Current Report Filing (8-k)
April 08 2019 - 4:40PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
Current
Report
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
April 5, 2019
ANAVEX
LIFE SCIENCES CORP.
(Exact name of registrant as specified in its charter)
Nevada
|
001-37606
|
98-0608404
|
(State or other jurisdiction
|
(Commission
|
(IRS Employer
|
of incorporation)
|
File Number)
|
Identification No.)
|
51
West 52nd Street, 7th Floor, New York, NY USA 10019
(Address of principal executive offices) (Zip Code)
Registrant's
telephone number, including area code
1-844-689-3939
Not
Applicable
(Former name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR
§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07.
|
Submission of Matters
to a Vote of Security Holders.
|
On
April 5, 2019, Anavex Life Sciences Corp., a Nevada corporation (the “
Company
”), held a special meeting of
stockholders (the “
Meeting
”) as prescribed in the Proxy Statement filed by the Company with the Securities
and Exchange Commission on February 11, 2019. At the Meeting, four proposals were submitted for a vote of the Company’s
stockholders and the related results are as follows:
Proposal
No. 1
: The election of Christopher Missling, Ph.D., Athanasios Skarpelos, Elliot Favus, M.D., Steffen Thomas, Ph.D., Peter
Donhauser, D.O., and Claus van der Velden, Ph.D. for terms until the next annual meeting of stockholders or until each such director’s
successor shall have been duly elected and qualified
. The stockholders elected each of the six directors by the following
votes:
Director
|
Votes
For
|
Votes
Withheld
|
Broker
Non-Votes
|
Christopher Missling, Ph.D.
|
26,247,560
|
259,642
|
13,699,223
|
Athanasios Skarpelos
|
26,142,629
|
364,573
|
13,699,223
|
Elliot Favus, M.D.
|
26,261,843
|
245,359
|
13,699,223
|
Steffen Thomas, Ph.D.
|
26,120,119
|
387,083
|
13,699,223
|
Peter Donhauser, D.O.
|
26,140,899
|
366,303
|
13,699,223
|
Clause van der Velden, Ph.D.
|
26,101,365
|
405,837
|
13,699,223
|
Proposal
No. 2
: Amendment of the Company’s Articles of Incorporation to Authorize Up To 10,000,000 Shares of Blank Check Preferred
Stock.
The stockholders approved the amendment of the Company’s Articles of Incorporation to authorize up to 10,000,000
shares of blank-check preferred stock of the Company as follows
:
Votes For
|
23,935,988
|
Votes Against
|
2,296,194
|
Abstentions
|
275,020
|
Broker Non-Votes
|
13,669,223
|
Proposal
No. 3
: Approval of Anavex Life Sciences Corp. 2019 Omnibus Incentive Plan
. The proposal was approved as follows:
Votes For
|
24,301,021
|
Votes Against
|
1,839,727
|
Abstentions
|
366,454
|
Broker Non-Votes
|
13,669,223
|
Proposal
No. 4
: Ratification of Independent Registered Public Accounting Firm
. The stockholders ratified BDO USA, LLP as the Company’s
independent registered public accounting firm as follows:
Votes For
|
39,679,132
|
Votes Against
|
256,342
|
Abstentions
|
240,951
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
ANAVEX LIFE SCIENCES CORP.
|
|
|
|
/s/
Christopher Missling
|
|
Name: Christopher Missling, PhD
|
|
Title: Chief Executive Officer
|
|
|
Date: April 8, 2019
|
|
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Apr 2023 to Apr 2024